According to the prescribing information for
PsA, etanercept should be administered at 50 mg weekly and adalimumab should be administered at 40 mg every other week (EOW) [12, 13] . 
METHODS

Study Design
This retrospective cohort study used administrative claims data from a large, national United States (US) Conclusions: Approximately half of PsA patients were persistent on their index TNF-blocker for 12 months. Pauses in therapy and therapy discontinuation were common, but more than 40% of patients restarted their index TNFblocker after discontinuation.
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INTRODUCTION
Psoriatic arthritis (PsA) is a chronic, immunemediated, inflammatory disease with a wide global variation in prevalence, ranging up to 420 cases per 100,000 people [1] . Joint swelling and pain associated with PsA have a substantial negative impact on health-related quality of life [2, 3] . Patients with PsA experience continuing disability, resulting in high rates of unemployment and work disability [4, 5] . PsA is associated with significant socioeconomic and healthcare costs, which increase with disease severity and age [6] [7] [8] .
Tumor necrosis factor (TNF) (4) other (e.g., switched to another biologic and then switched back to index medication). 
Statistical Analysis
RESULTS
Patient Characteristics and Initial Dose
Among 346 
Study Measures
The initial TNF-blocker dose was defined 
Therapy Persistence
In This rate is higher than the persistence rates observed in the present study's US population (50% of patients on etanercept and 45% of patients on adalimumab). This difference may be attributable to the definition of persistence used in each study; gaps in therapy up to 3 months were allowed in the BSRBR study, to accommodate treatment of infections or for elective surgery, whereas patients in the present study were considered discontinued if they did not restart index medication after a 60-day gap [14] . The rates of discontinuation without switch or restart were similar between the BSRBR study (24.5%) [14] 
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